ABOS

$2.79-$0.13 (-4.45%)prev close

Compare

Change$-13.39

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$211.2M

72M shares

52-week range

$1.21 – $3.60

66% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-1.53	$-1.64–$-1.45	—	3
2027	$0	—	$-1.48	$-1.93–$-1.22	—	3
2028	$4M	—	$-1.18	$-1.57–$-0.79	—	2
2029	$56M	+1353.4%	$-0.73	$-0.73–$-0.73	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.36	$-0.45	-25.2%
2026-05-12	$-0.40	$-0.33	+18.1%
2026-03-26	$-0.50	$-0.41	+18.0%
2025-11-12	$-0.63	$-0.44	+30.2%
2025-08-12	$-0.54	$-0.68	-25.9%
2025-05-13	$-0.56	$-0.48	+14.3%
2025-03-27	$-0.47	$-0.62	-31.9%
2024-11-12	$-0.36

DCF fair valuemodel estimate

Intrinsic value

$0.38

Price

$2.79

Implied downside

-87%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ABOSAcumen Pharmaceuticals, Inc.	$2.79	-4.45%	$202M	—
ACTUActuate Therapeutics Inc	$1.03	-3.74%	$25M	—
AGENAgenus Inc.	$7.13	+2.74%	$297M	—
ALECAlector, Inc.	$2.21	+3.27%	$245M	—
FATEFate Therapeutics, Inc.	$2.34	+1.30%

Acumen Pharmaceuticals, Inc. Common Stock

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

www.acumenpharm.com

Employees: 61
IPO / List date: Jul 1, 2021
HQ: NEWTON, MA

Held by traders on TradeandTell

No one on the platform currently holds ABOS.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	473,946	$1.1M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ABOS yet.

$ABOS chatter on StockTwits

Tom@Brookwood84d
$ABOS 🔥 NEW takeaways from Cantor: 🔥 >95% of eligible ALTITUDE patients are rolling into the OLE for another year of treatment. Management also said retention/dropout is better than expected. NOT proof of efficacy, but very encouraging engagement/tolerability heading into the readout. 🔥 ALTITUDE could determine the next-gen EBD strategy. A positive result may influence whether ABOS advances the sabirnetug-based construct or ACU401. 🔥 They retain BOTH EBD opportunities. Selecting one doesn't eliminate their ability to develop the other. 🔥 Management's 12-month goal: a “robust and successful” ALTITUDE outcome validating the oligomer hypothesis + EBD moving toward first patient dosing in 2H27. >95% OLE rollover was the standout new datapoint for me. 🎯
View on StockTwits ↗
DoyourDD@betonthenewsAug 27
$ABOS 19th Clinical Trials on Alzheimer's Disease (CTAD) November 16-19, 2026 Boston, MA (United States)
View on StockTwits ↗
DoyourDD@betonthenewsAug 27
$ABOS Q2 earning CC: Dan O'Connell CEO at Acumen Pharmaceuticals 00:06:42 Coming up, I'd like to flag for investors an anticipated virtual investor relations day to be held on September 16th. Please mark your calendars to view live or as a recording, as we hope this will be helpful review for the Acumen investment thesis prior to ALTITUDE-AD's phase II data readout.
View on StockTwits ↗
CMWYW@JuggernautRaiderBullishAug 26
$VYGR $TLSA $CGTX $ABOS these are my favorite four cognitive biotechs. Given I played football and have mild CTE and likely early onset Parkinson’s… i want to get more into neuroscience biotechs. Which am I missing? I keep studying the sector and these are my core four. Thanks! 🧠 💨 💊 💉 😯 🧫 😊 🦴 🍴 The BONESAW OF bioTech ~ thee Jay Sizzled 🎶
View on StockTwits ↗
Andy Luu@Kingcrab33333BullishAug 22
$ABOS
View on StockTwits ↗
G Hot@GeohotventuresBullishAug 19
$ABOS Let's go!
View on StockTwits ↗
David Smith@Stockley_BulbousberriesBullishAug 19
$ABOS Nice to be back over $3
View on StockTwits ↗
pir@SannieVerraderlijkAug 13
$ABOS If Leqembi is a 5B peak sales drug in Alzheimer's and Sabirnetug turns out to be a better Leqembi (roughly the aim here) when data reads out in Q4 26, what kind of price action will we see considering this is currently trading at around 70M EV?
View on StockTwits ↗
Tom@Brookwood8Aug 12
$ABOS “treatment of choice with a differentiated benefit-to-risk profile.” �
View on StockTwits ↗
MarketBeat Earnings@EarningsInsiderAug 12
https://www.marketbeat.com/earnings/reports/2026-8-12-acumen-pharmaceuticals-inc-stock/ $ABOS Acumen Pharmaceuticals Earnings Transcript
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarningsAug 12
$ABOS Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.45 up 33.82% YoY
View on StockTwits ↗
CE@selftaughtJul 22
$ABOS Watching again!
View on StockTwits ↗
PRISM MarketView@prismmarketviewJul 16
( $ABOS) @AcumenPharm is pushing its EBD™ bispecifics to the front of the AD pipeline: ACU401 delivered up to 40x higher frontal‑cortex exposure in primates with no anemia signals, setting up low‑volume subQ dosing in early Alzheimer’s just as ALTITUDE‑AD patient data highlight how urgently better brain‑penetrant therapies are needed. https://prismmarketview.com/companies/acumen-pharmaceuticals-inc/
View on StockTwits ↗
PRISM MarketView@prismmarketviewJul 15
$ABOS Acumen Pharmaceuticals just dropped new brain-delivery data at #AAIC2026. Its EBD candidate ACU401 hit up to 40x greater frontal cortex exposure in primates — with no anemia safety signals. A big step for its Alzheimer's pipeline. 🧠 #Alzheimers #Biotech #NASDAQ #ABOS https://prismmarketview.com/acumen-pharmaceuticals-advances-brain-delivery-platform-with-new-aaic-2026-data/
View on StockTwits ↗
Go for ProMIS@GoforProMISBullishJul 2
$PMN $ABOS Platform companies can achieve significantly higher market valuations than only Alzheimer targeting companies as Acumen! WHAT would it take for ProMIS to really take off? The market would need to become convinced that: * PMN310 is at least as effective as existing Alzheimer’s antibodies. * At the same time, it causes significantly less ARIA. * EpiSelect genuinely identifies disease-specific epitopes, including for alpha-synuclein and TDP-43. * Preclinical programs successfully advance to clinical trials. * A major pharmaceutical partner validates the platform through a collaboration or licensing agreement. In that case, ProMIS would no longer be valued merely as a company with a single Alzheimer’s project, but as a platform company with several blockbuster targeting diseases!
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.